Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Eli Lilly and Company’s LLY shares declined 6.6% on Tuesday after the company lowered its sales guidance for full-year 2024 ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

These high-quality businesses have suffered recent share price setbacks. This writer thinks they're now worth considering for a Stocks and Shares ISA.

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Danish investment firm Novo Holdings, which has invested in Manipal Hospitals and Qure.ai Technologies in India, has ...

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.

BofA maintained LLY at Buy and a price target of $997.0, but said it was reviewing its estimates on the stock.

The health-care sector has been rebounding recently following a sharp selloff in recent weeks amid hopes that controversy would die down. The health-care industry group was among the leading S&P 500 ...